Dow jumps with upbeat 3M, Caterpillar earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
3M (MMM) PT Raised to $257 at BofA/Merrill Lynch Following 3Q
October 25, 2017 9:34 AM EDTBofA/Merrill Lynch raised its price target on 3M (NYSE: MMM) to $257.00 (from $227.00) while maintaining a Buy rating following the company's 3Q. 3Ms EPS of $2.33 beat the consensus of $2.21. 3M recorded strategic investments of $48mn ($0.06/sh) in 3Q, below estimates of $0.11 but... More
3M (MMM) PT Raised to $209 at RBC Capital Following 3Q Beat
October 25, 2017 7:47 AM EDTRBC Capital raised its price target on 3M (NYSE: MMM) to $209.00 (from $205.00) while maintaining a Sector Perform rating following the company's 3Q release. The company reported a 12c EPS beat in the quarter. 3M achieved flat pricing in 3Q17, quelling some of the... More
Biogen (BIIB) Reports AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
October 25, 2017 5:56 AM EDTBiogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS). The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.
These data... More
